Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
about
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Drug exposure and the risk of multiple sclerosis: A systematic review.Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.
P2860
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@en
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@nl
type
label
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@en
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@nl
prefLabel
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@en
Risk of multiple sclerosis dur ...... h Multiple Sclerosis Registry.
@nl
P2093
P2860
P1476
Risk of multiple sclerosis dur ...... sh Multiple Sclerosis Registry
@en
P2093
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-208490
P407
P577
2015-12-23T00:00:00Z